The US HHS is allocating $2bn (€1.6bn) to overhaul pandemic and bioterrorism capabilities through improvements to regulatory, developmental and manufacturing processes.
SAFC and Novozymes Biopharma have agreed to extend their partnership by ten years for the exclusive distribution of LONG R3 growth factor, used for industrial cell culture applications.
Producing conjugate vaccines in recombinant E coli is potentially simpler and more cost-effective than alternatives, say researchers, but the method suffers from low yields.
US drugmaker Merck & Co has announced plans to reacquire a Pennsylvania manufacturing plant to guarantee supply of key active pharmaceutical ingredient (API).
Lower overseas demand from key customers hurt fine chemicals maker Synthetech in first quarter fiscal 2011, continuing the decline seen in the previous financial year
Ampac Fine Chemicals posted a 28 per cent jump in revenues in the third quarter but this was offset by manufacturing inefficiencies and validation costs.
Pfenex has won a US federal contract to use its expression technology for the rapid, cost-effective production of “unprecedented” amounts of anthrax vaccine.
Greater recognition of toxicity risks of HPAPIs and continued growth of oncology sector are driving drug industry demand for safe manufacturing capacity says US fine molecules firm SAFC Pharma.
Recently-acquired Italian R&D facility helps Aptuit win new contract after local neuroscience-focused developer Siena Biotech names the CMO as “supplier of choice.”
Colorcon will buy Indian group Pharmaceuitcal Coatings to expand both its tablet film coating business and presence in “rapidly growing” pharmaceutical market.
Indian contractor Terrene Pharma has filed a DMF for hard gelatin capsules with the US FDA, signalling its intention to expand in the world’s most lucrative drug market.
A group of Irish drug firms and banks plan to set up a “global pharmaceutical centre of excellence” (COE) that they believe will create 4,800 research, development and manufacturing jobs.
The Institute for OneWorld Health (iOWH) has moved one step closer to supplying a key component of a malaria treatment on an industrial scale as it revealed details of its latest activities to bring the ingredient to regions in short supply.
Prosonix has entered into an agreement with Trimel Biopharma, in which both companies will combine their respective technologies to deliver improved inhalation performance for respiratory medicines.
Merck & Co is to close or sell eight manufacturing plants and a further eight R&D laboratories as part of efforts to cuts its workforce by 15 per cent.
The rapidly evolving Asian drug manufacturing sector represents both an opportunity and a challenge for the fine chemicals and molecules industry, according to SAFC president Gilles Cottier.
The potential of microbial cells as producers of nanomaterials has been underestimated and further research is needed to improve the situation, according to an academic.
Chemicals manufacturer BASF reorganises Swiss business to cut active pharmaceutical ingredient (API) manufacturing site complexity and simplify process operations.
Suzhou Erye, a subsidiary of NeoStem Pharmaceutical, has passed inspection by the Chinese Food and Drug Administration (SFDA) meaning the company's new manufacturing facility will go ahead with the manufacture of penicillin and cephalosporin powder...
India’s oldest pharmaceutical company Alembic went one step closer to the biggest restructuring in its history as its board approved the demerging of its main pharmaceutical business into a separate subsidiary company, Alembic Pharma.
Sanofi-Aventis will build a new manufacturing plant in King Abdullah Economic City (KAEC) in Saudi Arabia through an agreement with the Emaar development company (ECC).
ViroPharma is seeking permission from the Food and Drug Administration (FDA) to increase production of Cinryze to an industrial scale as part of its ongoing expansion activities.
Pfizer continues its foray into rare diseases as it creates a new R&D unit to investigate novel therapeutics for conditions such as Haemophilia. The pharma giant joins GlaxoSmithKline and Novartis as companies looking into producing specialised drugs...
Parabolic Drugs will enter India’s CRAMS sector with new dedicated manufacturing facilities designed to attract “global innovator companies” enabling its business to grow in regulated markets.
GlaxoSmithKline (GSK) has described media reports of an overall review of operations in Ireland as “completely inaccurate”, telling in-PharmaTechnologist that the exercise only covers the plant in Cork.
KV Pharmaceuticals has decided to cut its losses and sell its subsidiary Particle Dynamics in a deal worth $24.6m (€20.6m). The deal adds some much needed stability as the business attempts to shore up its finances during a difficult period.
The USP is strengthening links with Eastern Europe and Russia by agreeing to share quality standards with Ukraine and offering training courses in Moscow.
Indian API manufacturer Shasun Chemicals and Drugs turned a previous loss into profit for Q4 of this year as it seeks to make a dent in the biosimilar manufacturing sector.
India-based Surya Pharmaceuticals is planning to raise Rs 500 crore ($100m) to fund construction of an active pharmaceutical ingredient (API) production plant, according to local media reports.
ISP Pharmaceuticals has expanded its extrusion spheronisation offering with the installation of new dedicated technology at its laboratory in Sao Paulo, Brazil.
Lanxess has signalled its intentions for the future by investing €35m ($43m) to expand its German Basic Chemicals business unit in a move that is set to make the firm one of Europe’s biggest active pharmaceutical ingredients (API) producers.
Cevec has exclusively licensed its transient CAP-T cell expression technology to Pevion for the manufacture and commercialisation of a protein antigen to vaccinate against an infectious disease.
DPT Laboratories has added bulk production and packaging capacity at its liquid and semi-solids plant in San Antonio, Texas in a continuation of its recent manufacturing reorganisation.
